Skip to main content
Oxford University Press - PMC COVID-19 Collection logoLink to Oxford University Press - PMC COVID-19 Collection
. 2022 Jun 14:ciac481. doi: 10.1093/cid/ciac481

Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons

Nischal Ranganath 1, John C O’Horo 2,3, Douglas W Challener 4, Sidna M Tulledge-Scheitel 5, Marsha L Pike 6, R Michael O’Brien 7, Raymund R Razonable 8, Aditya Shah 9,
PMCID: PMC9384250  PMID: 35698452

ABSTRACT

In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for coronavirus disease-2019, two patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.


Articles from Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America are provided here courtesy of Oxford University Press

RESOURCES